Bravo! Bravo! Bravo! European Parliament to Investigate WHO & “Pandemic” Scandal

NOTE FROM Ann Blake-Tracy:

Well it appears that Senator Grassley’s persistent questioning
about ties between academic scientists, the pharma industry, and the
FDA has caught on in Europe. The EU Parliment has UNANIMOUSLY called for an
investigation and now the hard questions are having to be answered in the
bogus Swine Flu Pandemic.
And as we were warned in Rev. 18:23 & 24 this great
deception that will cover the earth in our day concerning “sorceries” (the Greek
translation being “pharmakia” – meaning medicine from a pharmacy) is
becoming more obvious by the minute as we are shown the close ties
between those who are suppose to declare safety, science and truth about them
and those who profit from them.
The reason for the deception
is made clear as day – $$$$$$$.
With new information continuing to come out and estimates that
50% of the new medical research is not real research, but instead bogus
infomercials that have been ordered and paid for by the drug industry, it is
apparent that t
his whole medical-industrial complex is
completely broken and corrupt to the core!
Ann Blake-Tracy
_____________________________
The Health Committee of the EU Parliament has
unanimously passed a resolution calling for the inquiry. The step is a
long-overdue move to public transparency of a “Golden Triangle” of drug
corruption between WHO [World Health Organization], the pharma industry and
academic scientists that has permanently damaged the lives of millions and even
caused death.

European Parliament to Investigate WHO and “Pandemic”
Scandal

  • Text
    size
  • javascript:increaseFontSize();
  • javascript:decreaseFontSize();

F.
William Engdahl

Global Research
December 31, 2009

The
Council of Europe member states will launch an inquiry in January 2010 on the
influence of the pharmaceutical companies on the global swine flu campaign,
focusing especially on extent of the pharma‘s industry’s influence on WHO. The
Health Committee of the EU Parliament has unanimously passed a resolution
calling for the inquiry. The step is a long-overdue move to public transparency
of a “Golden Triangle” of drug corruption between WHO, the pharma industry and
academic scientists that has permanently damaged the lives of millions and even
caused death.

The
parliament motion was introduced by Dr. Wolfgang Wodarg, former SPD Member of
the German Bundestag and now Chairman of the European Parliament Health
Committee. Wodarg is a medical doctor and epidemiologist, a specialist in lung
disease and environmental medicine, who considers the current “pandemic” Swine
Flu campaign of the WHO to be “one of the greatest medicine scandals of the
Century.”[1]

The text of the resolution just passed by a sufficient number in the
Council of Europe Parliament says among other things, “In order to promote their
patented drugs and vaccines against flu, pharmaceutical companies influenced
scientists and official agencies, responsible for public health standards to
alarm governments worldwide and make them squander tight health resources for
inefficient vaccine strategies and needlessly expose millions of healthy people
to the risk of an unknown amount of side-effects of insufficiently tested
vaccines. The “bird-flu”-campaign (2005/06) combined with the
“swine-flu”-campaign seem to have caused a great deal of damage not only to some
vaccinated patients and to public health-budgets, but to the credibility and
accountability of important international health-agencies.”[2]

The
Parliamentary inquiry will look into the issue of „falsified pandemic“ that was
declared by WHO in June 2009 on the advice of its group of academic experts,
SAGE, many of whose members have been documented to have intense financial ties
to the same pharmaceutical giants such as GlaxoSmithKline, Roche, Novartis, who
benefit from the production of drugs and untested H1N1 vaccines. They will
investigate the influence of the pharma industry in creation of a worldwide
campaign against the so-called H5N1 “Avian Flu” and H1N1 Swine Flu. The inquiry
will be given “urgent” priority in the general assembly of the parliament.

In
his official statement to the Committee, Wodarg criticized the influence of the
pharma industry on scientists and officials of WHO, stating that it has led to
the situation where “unnecessarily millions of healthy people are exposed to the
risk of poorly tested vaccines,” and that, for a flu strain that is “vastly less
harmful” than all previous flu epidemics.

Wodarg
says the role of the WHO and its the pandemic emergency declaration in June
needs to be the special focus of the European Parliamentary inquiry. For the
first time, the WHO criteria for a pandemic was changed in April 2009 as the
first Mexico cases were reported, to make not the actual risk of a disease but
the number of cases of the disease basis to declare “Pandemic.” By classifying
the swine flu as pandemic, nations were compelled to implement pandemic plans
and also the purchase swine flu vaccines. Because WHO is not subject to any
parliamentary control, Wodarg argues it is necessary for governments to insist
on accountability. The inquiry will also to look at the role of the two critical
agencies in Germany issuing guidelines on the pandemic, the Paul-Ehrlich and the
Robert-Koch Institute.

Bravo!

2/7/2002 • Scandal of scientists who take money for papers ghostwritten by drug companies

2/7/2002 • Scandal of scientists who take money for papers ghostwritten by drug companies

Sarah Boseley
health editor

Guardian

Scientists are accepting large sums of money from drug companies to put their names to articles endorsing new medicines that they have not written – a growing practice that some fear is putting scientific integrity in jeopardy.

Scandal of scientists who take money for papers ghostwritten by drug companies

http://www.guardian.co.uk/Archive/Article/0,4273,4351264,00.html

Sarah Boseley
health editor

Guardian

Scientists are accepting large sums of money from drug companies to put their names to articles endorsing new medicines that they have not written – a growing practice that some fear is putting scientific integrity in jeopardy.

Ghostwriting has become widespread in such areas of medicine as cardiology and psychiatry, where drugs play a major role in treatment. Senior doctors, inevitably very busy, have become willing to “author” papers written for them by ghostwriters paid by drug companies.

Originally, ghostwriting was confined to medical journal supplements sponsored by the industry, but it can now be found in all the major journals in relevant fields. In some cases, it is alleged, the scientists named as authors will not have seen the raw data they are writing about – just tables compiled by company employees.

The doctors, who may also give a talk based on the paper to an audience of other doctors at a drug company-sponsored symposium, receive substantial sums of money. Fuller Torrey, executive director of the Stanley Foundation Research Programmes in Bethesda, Maryland, found in a survey that British psychiatrists were being paid around $2,000 (£1,400) a time for symposium talks, plus airfares and hotel accommodation, while Americans got about $3,000. Some payments ran as high as $5,000 or $10,000. “Some of us believe that the present system is approaching a high-class form of professional prostitution,” he said.

Robin Murray, head of the division of psychological medicine at the Institute of Psychiatry in London, is one of those who has become increasingly concerned. “It is clear that we have a situation where, when an audience is listening to a well-known British psychiatrist, you recognise the stage where the audience is uncertain as to whether the psychiatrist really believes this or is saying it because they themselves or their department is getting some financial reward,” he said. “I can think of a well-known British psychiatrist I met and I said, ‘How are you?’ He said, ‘What day is it? I’m just working out what drug I’m supporting today.'”

Marcia Angell, former editor of the New England Journal of Medicine, wrote a year ago that when she ran a paper on antidepressant drug treatment, the authors’ financial ties to the manufacturers – which the journal requires all contributors to declare – were so extensive that she had to run them on the website. She decided to commission an editorial about it and spoke to research psychiatrists, but “we found very few who did not have financial ties to drug companies that make antidepressants.”

She wrote: “Researchers serve as consultants to companies whose products they are studying, join advisory boards and speakers’ bureaus, enter into patent and royalty arrangements, agree to be the listed authors of articles ghostwritten by interested companies, promote drugs and devices at company-sponsored symposiums, and allow themselves to be plied with expensive gifts and trips to luxurious settings. Many also have equity interest in the companies.”

In September her journal joined the Lancet and 11 others in denouncing the drug companies for imposing restrictions on the data to which scientists are given access in the clinical trials they fund. Some of the journals propose to demand a signed declaration that the papers scientists submit are their own.

The success of Prozac, the antidepressant which became a cult “happy” drug in the 1990s, substantially raised the stakes in psychiatry. Its promotion coincided with the decline of state funding for research, leaving scientists in all areas of medicine dependent on pharmaceutical companies to fund or commission their work. That in turn gave the industry unprecedented control over data and ended with research papers increasingly being drafted by company employees or commercial agencies.

The responsibility of scientists for the content of their papers takes on serious significance in the context of court cases in the US, where relatives of people who killed themselves and murdered others while on SSRIs (selective serotonin reuptake inhibitors) – the class of drug to which Prozac belongs – claimed the drugs were responsible.

According to David Healy, a north Wales-based psychopharmacologist who has given evidence for the families, the companies have relied on articles apparently authored by scientists who may in fact have not seen the raw data.

Dr Healy, who had unprecedented access to the data that the companies keep in their archives, said: “It may well be that 50% of the articles on drugs in the major journals across all areas of medicine are not written in a way that the average person in the street expects them to be authored.” He cites the case brought last year against the former SmithKline Beecham (now GlaxoSmithKline) by relatives of Donald Schell. The court found that the company’s best-selling antidepressant, an SSRI called Seroxat, had caused Schell to murder his wife, daughter and granddaughter and commit suicide.

The company’s defence was based on scientific papers which analysed the results of trials comparing Seroxat with a placebo and found there was no increased risk of suicide for depressed people on Seroxat. But the raw data probably does not support that, argues Dr Healy. Some of the placebo suicides took place while patients were withdrawing from an older drug. When the figures are readjusted without these, he says, they show there is substantially increased risk of suicide on Seroxat.

This raises the question of whether the eminent scientists whose names were on the papers ever saw the raw data from the trials – or saw only tables compiled by company employees, he says.

David Dunner, a professor at the University of Washington, who co-authored one of the papers in 1995, admits he did not see the raw data. “I don’t know who saw it. I did not,” he said. “My role in the paper was that the data were presented to us and we analysed it and wrote it up and wrote references.” His co-author Stuart Montgomery, then of St Mary’s hospital medical school in London, declined to answer calls and emails from the Guardian. The third name on the paper is that of Geoff Dunbar, a company employee.

The World Health Organisation has expressed concern about the ties between industry and researchers. Jonathan Quick, director of essential drugs and medicines policy, wrote in the latest WHO Bulletin: “If clinical trials become a commercial venture in which self-interest overrules public interest and desire overrules science, then the social contract which allows research on human subjects in return for medical advances is broken.”

Guardian Unlimited © Guardian Newspapers Limited 2002